source
- Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitisBoth Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
- Novartis CEO says AI could cut drug development time and boost success ratesAt an investor event in London, Novartis chief executive Vas Narasimhan, who also sits on the board of AI company Anthropic, explained how the Swiss drugmaker is turning to artificial intelligence…